RESEARCH PAPER
Afamin and adropin in patients with alcohol-induced liver cirrhosis
 
More details
Hide details
1
Department of Internal Medicine, Medical University of Lublin, Lublin, Poland
2
Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland
3
Department of Medical Chemistry, Medical University of Lublin, Lublin, Poland
4
Department of Ethics and Human Philosophy, Medical University of Lublin, Lublin, Poland
5
Independent Public Teaching Hospital No 4 in Lublin, Poland
6
Students' Scientific Society, Medical University of Lublin, Lublin, Poland
7
Department of Internal Diseases and Hypertension, Institute of Rural Medicine, Lublin, Poland
8
Department of Nephrology, Medical University of Lublin, Lublin, Poland
 
KEYWORDS:
TOPICS:
ABSTRACT:
The aim of the study was to determine serum concentrations of afamin and adropin in patients with alcoholic liver cirrhosis and to define their correlation with the stage of disease. The study included 99 patients with alcoholic cirrhosis from the region of Lublin, (Eastern Poland). Liver cirrhosis was diagnosed based on clinical features, history of heavy alcohol consumption, laboratory tests and abdominal ultrasonography. The control group consisted of 20 healthy individuals without liver disease who did not abuse alcohol. The serum afamin and adropin concentrations were determined using ELISA kits. The concentration of afamin was found to be significantly lower in patients with compensated alcoholic liver cirrhosis, i.e. P-Ch B (85.1±40.6 μg/ml) and P-Ch C (56.4±32.3 μg/ml) individuals, compared to the control group (135.9±43.6 μg/ml); p-value was <0.01 and <0.001, respectively. As far as adropin is concerned, a reverse relationship was demonstrated: the highest concentration was found in patients with P-Ch C (11.7±5.7 ng/ml) cirrhosis. Furthermore, the above concentration was significantly higher compared to patients with P-Ch A cirrhosis (7.2±2.8 ng/ml; p<0.05) and controls (7.5±2.6 ng/ml; p<0.05). The concentration of afamin decreases with the severity of alcoholic liver cirrhosis, which most likely results from impaired hepatic synthesis. Otherwise, the higher the stage of disease according to the Child-Pugh score, the higher the concentration of adropin.
CORRESPONDING AUTHOR:
Andrzej Prystupa   
Department of Internal Medicine, Medical University of Lublin, Lublin, Poland, Staszica, 20-950 Lublin, Poland
 
REFERENCES (20):
1. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014; 12: 14, doi: 10.1186/s12916–014–0145-y.
2. Seth D, D’Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS. Alcohol, signaling, and ECM turnover. Alcohol Clin Exp Res. 2010; 34: 4–18.
3. Zhou W-C, Zhang Q-B, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014; 20(23): 7312–7324.
4. Ishii H, Horie Y, Yamagshi Y, Ebinuma H. Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome. JMAJ 2010; 53: 236–242.
5. Seeber B, Morandell E, Lunger F, Wildt L, Dieplinger H: Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. Reprod Biol Endocrinol. 2014; 12: 88, doi: 10.1186/1477–7827–12–88.
6. Kronenberg F, Kollerits B, Kiechl S, Lamina C, Kedenko L, Meisinger C, Willeit J, Huth C, Wietzorrek G, Altmann ME, et al. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet 2014; 7:822–829, doi:10.1161/CIRCGENETICS.113.000654.
7. Marczuk N, Cecerska-Heryć E, Jesionowska A, Dołęgowska B. Adropin – physiological and pathophysiological role. Postepy Hig Med Dosw. 2016; 70: 981–988.
8. Zhao LP, You T, Chan SP, Chen JC. Xu WT. Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Exp Ther Med. 2016; 11: 1065–1070.
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60: 646–649.
10. Lichenstein HS, Lyons DE, Wurfel MM, Johnson DA, McGinley MD, Leidli JC, Trollinger DB, Mayer JP, Wright SD, Zukowski MM. Afamin is a new member of the albumin, a-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem. 1994; 269: 18149–18154.
11. Dieplinger H, Dieplinger B. Afamin--A pleiotropic glycoprotein involved in various disease states. Clin Chim Acta. 2015; 446: 105–110, doi: 10.1016/j.cca.2015.04.010.
12. Kollerits B, Lamina C, Huth C, Marques-Vidal P, Kiechl S, Seppälä I, Cooper J, Hunt S, Meisinger C, Herder C, et al. Plasma Concentrations of Afamin Are Associated With Prevalent and Incident Type 2 Diabetes: A Pooled Analysis in More Than 20,000 Individuals. Diabetes Care 2017l; 40:1386–1393, doi: 10.2337/dc17–0201.
13. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H and Stieber P. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1127–1133.
14. Dieplinger B, Egger M, Gabriel C, Poelz W, Morandell E, Seeber B, Kronenberg F, Haltmayer M, Mueller T, Dieplinger H. Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma. Clin Chim Acta. 2013; 425: 236–241, doi: 10.1016/j.cca.2013.08.016.
15. Lee JS. Albumin for End-Stage Liver Disease. Korean J Intern Med. 2012; 27: 13–19, doi:10.3904/kjim.2012.27.1.13.
16. Kumar KG, Trevaskis J, Lam D, Sutton G, Koza R, Chouljenko V, Kousoulas K, Rogers P, Kesterson R, Thearle M, et al. Identification of Adropin as a Secreted Factor Linking Dietary Macronutrient Intake with Energy Homeostasis and Lipid Metabolism. Cell Metabolism. 2008; 8: 468–481.
17. Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides 2014; 56: 94–110, doi: 10.1016/j.peptides.2014.03.021, 2014.
18. Sayın O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2014; 27: 479–484, doi:10.1515/jpem-2013–0296.
19. Lian W, Gu X, Qin Y, Zheng X. Elevated Plasma Levels of Adropin in Heart Failure Patients. Intern Med. 2011; 50: 1523–1527, doi: 10.2169/internalmedicine.50.5163.
20. Hu W, Chen L. Association of Serum Adropin Concentrations with Diabetic Nephropathy. Mediators Inflamm. 2016; 6038261, doi: 10.1155/2016/6038261.
eISSN:1898-2263
ISSN:1232-1966